All In Biotech

Drug Trial Radar · NCT00312377

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

Last checked: Nov 20, 2026Latest source record: Sep 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,690 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,690

Actual

Start

May 2006

Primary completion

Aug 2008

Study completion Mar 2014

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.

Conditions

  • Non-small Cell Lung Cancer
  • Lung Cancer

Interventions

  • DocetaxelDrug

    infusion

  • VandetanibDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) in the Overall PopulationTime frame: RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
  2. Progression-Free Survival (PFS) in the Female PopulationTime frame: RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months

Locations

156 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Fullerton, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Ocala, Florida

  • Research Site

    Marietta, Georgia

  • Research Site

    Joliet, Illinois

  • Research Site

    Park Ridge, Illinois

  • Research Site

    Hutchinson, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Henderson, Nevada

  • Research Site

    Albany, New York

  • Research Site

    Armonk, New York

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Hickory, North Carolina

  • Research Site

    Portland, Oregon

  • Research Site

    Austin, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Ogden, Utah

  • Research Site

    Alexandria, Virginia

  • Research Site

    Salem, Virginia

  • Research Site

    Vancouver, Washington

  • Research Site

    Bahía Blanca, Argentina

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Graz, Austria

  • Research Site

    Grimmenstein, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Wels, Austria

  • Research Site

    Brussels (Jette), Belgium

  • Research Site

    Brussels (Woluwé-St-Lambert), Belgium

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.